Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC (Nasdaq: ORIC) reported Phase 1b data for enozertinib (ORIC-114) in EGFR exon 20 NSCLC at ESMO Asia Congress 2025 on Dec 6, 2025. Key efficacy: 1L best ORR 67% (60% confirmed in initial cohort) and 100% intracranial confirmed ORR by BICR-RANO; 2L confirmed ORR 45% in the 80 mg cohort. Safety: mostly Grade 1–2 TRAEs, low discontinuation (2 in 1L, 3 in 2L), more dose reductions at 120 mg. Follow-up median ~30–33 weeks. Company selected 80 mg QD for potential Phase 3; enrollment continues with next update expected mid-2026. Conference call and webcast held Dec 6, 2025 at 8:00 pm ET.
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity grants on December 1, 2025 to three newly hired non-executive employees who began in November 2025. The company granted 69,200 non-qualified stock options and 11,400 restricted stock units under the 2022 Inducement Equity Incentive Plan, subject to continued service through vesting dates.
The stock options use an exercise price equal to ORIC’s closing common stock price on the grant date. Options vest 25% after one year, then monthly at 1/36th of the remainder; RSUs vest one-third on each of the first three anniversaries. Grants were approved by the Compensation Committee per Nasdaq Rule 5635(c)(4) as material inducements to employment.
ORIC (NASDAQ: ORIC) reported Phase 1b data for oral enozertinib in previously treated NSCLC patients with HER2 exon 20 mutations presented at ESMO Asia Congress 2025. As of Aug 29, 2025, 49 patients were dosed (26 at 80 mg QD; 23 at 120 mg QD), with 47% having baseline brain metastases.
Key results in the 80 mg cohort: 35% ORR (26% confirmed ORR) and 100% disease control rate; manageable safety with mostly Grade 1–2 TRAEs and only 2 discontinuations. Median follow-up was 50 weeks; 32% of patients remained on treatment. Enrollment in HER2 exon 20 completed and no further development planned for that population; 80 mg QD selected for potential Phase 3 based on related cohorts.
ORIC (Nasdaq: ORIC) reported Phase 1b data for enozertinib (ORIC-114) at ESMO Asia Congress 2025 showing strong systemic and CNS activity in NSCLC with EGFR atypical and PACC mutations. In previously treated patients with PACC mutations (22 efficacy-evaluable), enozertinib achieved a 36% confirmed ORR and 91% DCR with median follow-up >32 weeks. In preliminary 1L PACC patients (10 efficacy-evaluable at 80 mg QD) the drug showed 80% ORR and 100% intracranial ORR in measurable CNS disease. Safety was manageable, with no TRAE-related discontinuations; 80 mg QD selected as the potential Phase 3 dose and next update expected mid-2026.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced two late-breaking oral presentations of Phase 1b data for enozertinib (ORIC-114) at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).
The mini-oral (LBA15) on Dec 5, 2025 at 11:38–11:43 a.m. SGT covers previously treated EGFR atypical mutant NSCLC with randomized dose optimization and CNS activity. The proffered paper oral (LBA13) on Dec 6, 2025 at 10:02–10:12 a.m. SGT covers EGFR exon 20 mutant NSCLC in previously treated and treatment-naïve patients. ORIC will host a conference call and webcast on Dec 6, 2025 at 8:00 p.m. ET, with a replay available for 90 days.
ORIC (Nasdaq: ORIC) will present clinical data for enozertinib (ORIC-114) in previously treated patients with HER2 exon 20 mutant NSCLC at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).
The poster (Presentation 981P) is scheduled for Friday, December 5, 2025, 5:15–6:15 p.m. SGT in a poster display session.
ORIC will host a related conference call and live webcast on Saturday, December 6, 2025 at 8:00 p.m. ET; live Q&A will require pre‑registration and the webcast replay will be available via ORIC’s investor website for 90 days.
ORIC Pharmaceuticals (Nasdaq: ORIC) said management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 11:15 a.m. ET and will hold one-on-one investor meetings.
The live webcast will be available via the company’s investor website and a replay will be accessible for 90 days after the event.
ORIC (Nasdaq: ORIC) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company completed dose exploration for ORIC-944 Phase 1b and selected provisional RP2Ds (400/600 mg with darolutamide; 600/800/1,200 mg with apalutamide). In 20 mCRPC patients, ORIC reported PSA50 55% (PSA90 20%) and ctDNA reductions: >50% in 76% and ctDNA clearance 59%. Safety profile compatible with long-term dosing; one Grade 3 TRAE, no Grade 4/5 attributed. Enozertinib INN approved; multiple Phase 1b cohorts enrolling. Corporate: CTO appointment and $413.0M cash/investments expected to fund operations into 2H 2028.
ORIC (Nasdaq: ORIC) reported Phase 1b dose exploration results for once-daily ORIC-944 combined with apalutamide or darolutamide in mCRPC on Nov 13, 2025. Key efficacy signals: PSA50 55% (11/20), PSA90 20% (4/20), rapid/deep ctDNA reductions in 76% (13/17) and ctDNA clearance in 59% (10/17). Safety was compatible with long-term dosing: most TRAEs Grade 1–2, one Grade 3 TRAE, no Grade 4/5 attributed to study drugs as of Sep 22, 2025. Provisional RP2Ds were selected and dose optimization data are expected in 1Q 2026, with a planned global Phase 3 start in 1H 2026.
ORIC Pharmaceuticals (Nasdaq:ORIC) disclosed inducement equity awards granted on November 3, 2025 to a new non-executive employee who started in October 2025. The company granted 18,400 non-qualified stock options and 3,000 restricted stock units (RSUs) under the 2022 Inducement Equity Incentive Plan, subject to continued service through vesting dates.
The stock options have an exercise price equal to ORIC's closing common-stock price on the grant date. Options vest 25% after one year, then 1/36th monthly thereafter; RSUs vest one-third on each of the first three anniversaries. Grants were approved by the Compensation Committee and made pursuant to Nasdaq Rule 5635(c)(4).
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
